In [3,5], the predictive biomarkers of ICI therapy have been comprehensively reviewed, including PD-L1 expression on cancer cells and other cells in the tumor microenvironment (TME), tumor mutational burden and other genetic and epigenetic factors, microbiome composition, IFN-γ signatures, and the composition and distribution of tumor-infiltrating lymphocytes. This evidence concerns the gene CD274 and neoplasm.